JP6799586B2 - 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ - Google Patents

遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ Download PDF

Info

Publication number
JP6799586B2
JP6799586B2 JP2018510914A JP2018510914A JP6799586B2 JP 6799586 B2 JP6799586 B2 JP 6799586B2 JP 2018510914 A JP2018510914 A JP 2018510914A JP 2018510914 A JP2018510914 A JP 2018510914A JP 6799586 B2 JP6799586 B2 JP 6799586B2
Authority
JP
Japan
Prior art keywords
spcas9
target
fusion protein
activity
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525019A (ja
JP2018525019A5 (enExample
Inventor
ジョン，ジェイ．キース
クラインスティーバー，ベンジャミン
パターナヤック，ヴィクラム
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/015,947 external-priority patent/US9512446B1/en
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2018525019A publication Critical patent/JP2018525019A/ja
Publication of JP2018525019A5 publication Critical patent/JP2018525019A5/ja
Application granted granted Critical
Publication of JP6799586B2 publication Critical patent/JP6799586B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018510914A 2015-08-28 2016-08-26 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ Active JP6799586B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562211553P 2015-08-28 2015-08-28
US62/211,553 2015-08-28
US201562216033P 2015-09-09 2015-09-09
US62/216,033 2015-09-09
US201562258280P 2015-11-20 2015-11-20
US62/258,280 2015-11-20
US201562271938P 2015-12-28 2015-12-28
US62/271,938 2015-12-28
US15/015,947 US9512446B1 (en) 2015-08-28 2016-02-04 Engineered CRISPR-Cas9 nucleases
US15/015,947 2016-02-04
PCT/US2016/049147 WO2017040348A1 (en) 2015-08-28 2016-08-26 Engineered crispr-cas9 nucleases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019153881A Division JP6745391B2 (ja) 2015-08-28 2019-08-26 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2020193171A Division JP7074827B2 (ja) 2015-08-28 2020-11-20 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2018525019A JP2018525019A (ja) 2018-09-06
JP2018525019A5 JP2018525019A5 (enExample) 2020-01-23
JP6799586B2 true JP6799586B2 (ja) 2020-12-16

Family

ID=58188120

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2018510914A Active JP6799586B2 (ja) 2015-08-28 2016-08-26 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2019153881A Active JP6745391B2 (ja) 2015-08-28 2019-08-26 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2020131422A Active JP6942848B2 (ja) 2015-08-28 2020-08-03 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2020193171A Active JP7074827B2 (ja) 2015-08-28 2020-11-20 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP2021145911A Active JP7326391B2 (ja) 2015-08-28 2021-09-08 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP2023125901A Active JP7731943B2 (ja) 2015-08-28 2023-08-02 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019153881A Active JP6745391B2 (ja) 2015-08-28 2019-08-26 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2020131422A Active JP6942848B2 (ja) 2015-08-28 2020-08-03 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
JP2020193171A Active JP7074827B2 (ja) 2015-08-28 2020-11-20 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP2021145911A Active JP7326391B2 (ja) 2015-08-28 2021-09-08 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP2023125901A Active JP7731943B2 (ja) 2015-08-28 2023-08-02 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Country Status (8)

Country Link
EP (2) EP4036236A1 (enExample)
JP (6) JP6799586B2 (enExample)
KR (2) KR20240090567A (enExample)
CN (2) CN108350449B (enExample)
AU (2) AU2016316845B2 (enExample)
CA (1) CA2996888A1 (enExample)
HK (1) HK1257676A1 (enExample)
WO (1) WO2017040348A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145657A (ja) * 2015-08-28 2023-10-11 ザ ジェネラル ホスピタル コーポレイション 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
KR102874079B1 (ko) 2013-03-15 2025-10-22 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
IL286474B2 (en) 2014-06-23 2023-11-01 Massachusetts Gen Hospital Genome-wide random identification of DSBS assessed by sequencing (guide-sequence)
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
KR102598856B1 (ko) 2015-03-03 2023-11-07 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
EP3347467B1 (en) 2015-09-11 2021-06-23 The General Hospital Corporation Full interrogation of nuclease dsbs and sequencing (find-seq)
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
JP2018529353A (ja) 2015-09-30 2018-10-11 ザ ジェネラル ホスピタル コーポレイション 配列決定法による切断事象の包括的生体外報告（ＣＩＲＣＬＥ−ｓｅｑ）
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3039409A1 (en) 2016-10-07 2018-04-12 Integrated Dna Technologies, Inc. S. pyogenes cas9 mutant genes and polypeptides encoded by same
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US12286727B2 (en) 2016-12-19 2025-04-29 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
EP3612551B1 (en) 2017-04-21 2024-09-04 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
CN108795989A (zh) * 2017-04-26 2018-11-13 哈尔滨工业大学 SpyCas9的基因编辑活性抑制位点及其抑制剂
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018218188A2 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
EP3650540B1 (en) * 2017-07-07 2025-04-16 Toolgen Incorporated Target-specific crispr mutant
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3672612A4 (en) 2017-08-23 2021-09-29 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES WITH MODIFIED PAM SPECIFICITY
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11530396B2 (en) 2017-09-05 2022-12-20 The University Of Tokyo Modified CAS9 protein, and use thereof
US20190218532A1 (en) * 2017-09-19 2019-07-18 Massachusetts Institute Of Technology Streptococcus Canis Cas9 as a Genome Engineering Platform with Novel PAM Specificity
EP3694993A4 (en) 2017-10-11 2021-10-13 The General Hospital Corporation SITE-SPECIFIC AND PARASITIC GENOMIC DESAMINATION DETECTION METHODS INDUCED BY BASIC EDITING TECHNOLOGIES
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
WO2019157326A1 (en) 2018-02-08 2019-08-15 Zymergen Inc. Genome editing using crispr in corynebacterium
CN109306361B (zh) * 2018-02-11 2022-06-28 华东师范大学 一种新的a/t到g/c碱基定点转换的基因编辑系统
EP3781585A4 (en) 2018-04-17 2022-01-26 The General Hospital Corporation SENSITIVE IN VITRO ASSAYS FOR SUBSTRATE AND SITE PREFERENCES OF NUCLEIC ACID BINDERS, MODIFIERS AND CLEAVATORS
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
BR112021000408A2 (pt) 2018-07-10 2021-06-29 Alia Therapeutics S.R.L. vesículas para dispensação sem traço de moléculas de rna guia e/ou complexo(s) de nuclease guiada por rna/molécula de rna guia e método de produção das mesmas
EP3853363A4 (en) * 2018-09-19 2022-12-14 The University of Hong Kong ENHANCED HIGH THROUGHPUT COMBINATORY GENE MODIFICATION SYSTEM AND OPTIMIZED CAS9 ENZYME VARIANTS
CN109265562B (zh) * 2018-09-26 2021-03-30 北京市农林科学院 一种切刻酶及其在基因组碱基替换中的应用
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
WO2020186059A2 (en) * 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020218657A1 (ko) * 2019-04-26 2020-10-29 주식회사 툴젠 표적 특이적 crispr 변이체
CN110272881B (zh) * 2019-06-29 2021-04-30 复旦大学 核酸内切酶SpCas9高特异性截短变异体TSpCas9-V1/V2及其应用
CN110577969B (zh) * 2019-08-08 2022-07-22 复旦大学 CRISPR/Sa-SlugCas9基因编辑系统及其应用
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US10883095B1 (en) * 2019-12-10 2021-01-05 Inscripta, Inc. Mad nucleases
CN112979822B (zh) * 2019-12-18 2022-11-15 华东师范大学 一种疾病动物模型的构建方法及融合蛋白
EP4079765A4 (en) * 2019-12-18 2024-02-14 East China Normal University FUSION PROTEIN TO IMPROVE GENE EDITING EFFICIENCY AND ITS USE
EP4093864A4 (en) 2020-01-24 2024-04-10 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
US12264341B2 (en) 2020-01-24 2025-04-01 The General Hospital Corporation CRISPR-Cas enzymes with enhanced on-target activity
JP2023519101A (ja) 2020-02-12 2023-05-10 マサチューセッツ アイ アンド イヤー インファーマリー Ｒｐ１関連網膜変性症のハプロタイプに基づく処置
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
WO2022026346A2 (en) * 2020-07-26 2022-02-03 Asc Therapeutics, Inc. Variants of cas nuclease
GB202019908D0 (en) * 2020-12-16 2021-01-27 Oxford Genetics Ltd Cripr polypeptides
CN112538471B (zh) * 2020-12-28 2023-12-12 南方医科大学 一种CRISPR SpCas9(K510A)突变体及其应用
CN112680430B (zh) * 2020-12-28 2023-06-06 南方医科大学 一种CRISPR SpCas9突变体及其应用
EP4326864A4 (en) * 2021-04-22 2025-06-18 Emendobio Inc. OMNI-17,140, 150-158,160-165,167-177,180-188,1921-92,205-201,215-201,221,2222,2236,239,229,239,285,245,26R
US20230279442A1 (en) * 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
AU2023222086A1 (en) 2022-02-18 2024-09-05 Dana-Farber Cancer Institute, Inc. Epitope engineering of cell-surface receptors
CN117384880A (zh) * 2022-07-08 2024-01-12 北京干细胞与再生医学研究院 工程化的核酸修饰编辑器
CN118956820B (zh) * 2024-05-10 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种Cas9蛋白突变体及在基因编辑技术中的应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325332B1 (en) 2005-08-26 2012-10-31 DuPont Nutrition Biosciences ApS Use of CRISPR associated genes (CAS)
NZ579002A (en) 2007-03-02 2012-03-30 Danisco Cultures with improved phage resistance
FR2925918A1 (fr) 2007-12-28 2009-07-03 Pasteur Institut Typage et sous-typage moleculaire de salmonella par identification des sequences nucleotidiques variables des loci crispr
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
MX337838B (es) 2008-11-07 2016-03-22 Dupont Nutrition Biosci Aps Secuencias de repetidos palindromicos cortos regularmente intercalados agrupados de bifidobacterias.
WO2010066907A1 (en) 2008-12-12 2010-06-17 Danisco A/S Genetic cluster of strains of streptococcus thermophilus having unique rheological properties for dairy fermentation
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
EA024121B9 (ru) 2010-05-10 2017-01-30 Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния Композиции эндорибонуклеаз и способы их использования
EP2630156B1 (en) 2010-10-20 2018-08-22 DuPont Nutrition Biosciences ApS Lactococcus crispr-cas sequences
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CN104284669A (zh) 2012-02-24 2015-01-14 弗雷德哈钦森癌症研究中心 治疗血红蛋白病的组合物和方法
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
FI3597749T3 (fi) 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
US9258704B2 (en) 2012-06-27 2016-02-09 Advanced Messaging Technologies, Inc. Facilitating network login
WO2014071235A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
PT3363902T (pt) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
EP2932421A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
EP4234696A3 (en) 2012-12-12 2023-09-06 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR20150105956A (ko) 2012-12-12 2015-09-18 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
PT2784162E (pt) 2012-12-12 2015-08-27 Broad Inst Inc Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
BR102013032129B1 (pt) 2012-12-13 2022-06-07 Dow Agrosciences Llc Método para identificar a presença de um polinucleotídeo de dna doador exógeno inserido dentro de um único locus genômico eucariótico alvo
EP4282970A3 (en) 2012-12-17 2024-01-17 President and Fellows of Harvard College Rna-guided human genome engineering
WO2014110552A1 (en) 2013-01-14 2014-07-17 Recombinetics, Inc. Hornless livestock
US20140212869A1 (en) 2013-01-25 2014-07-31 Agilent Technologies, Inc. Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
US10676749B2 (en) 2013-02-07 2020-06-09 The General Hospital Corporation Tale transcriptional activators
CA2901676C (en) 2013-02-25 2023-08-22 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
JP2016507244A (ja) 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273235A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
KR102874079B1 (ko) 2013-03-15 2025-10-22 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US20150056629A1 (en) 2013-04-14 2015-02-26 Katriona Guthrie-Honea Compositions, systems, and methods for detecting a DNA sequence
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
EP2994531B1 (en) 2013-05-10 2018-03-28 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US20150067922A1 (en) 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
WO2015010114A1 (en) 2013-07-19 2015-01-22 Larix Bioscience, Llc Methods and compositions for producing double allele knock outs
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
WO2015089364A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3079726B1 (en) 2013-12-12 2018-12-05 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
EP3080271B1 (en) * 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
CA2935032C (en) 2013-12-26 2024-01-23 The General Hospital Corporation Multiplex guide rnas
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
CN109536474A (zh) * 2015-06-18 2019-03-29 布罗德研究所有限公司 降低脱靶效应的crispr酶突变
AU2016316845B2 (en) * 2015-08-28 2022-03-10 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3374501B1 (en) * 2015-11-11 2023-07-12 Lonza Ltd Crispr-associated (cas) proteins with reduced immunogenicity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145657A (ja) * 2015-08-28 2023-10-11 ザ ジェネラル ホスピタル コーポレイション 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP7731943B2 (ja) 2015-08-28 2025-09-01 ザ ジェネラル ホスピタル コーポレイション 遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Also Published As

Publication number Publication date
AU2022203146B2 (en) 2024-08-29
JP2023145657A (ja) 2023-10-11
CN108350449A (zh) 2018-07-31
EP3341477B1 (en) 2022-03-23
JP7731943B2 (ja) 2025-09-01
JP6745391B2 (ja) 2020-08-26
JP7074827B2 (ja) 2022-05-24
HK1257676A1 (zh) 2019-10-25
CN114875012A (zh) 2022-08-09
JP7326391B2 (ja) 2023-08-15
EP4036236A1 (en) 2022-08-03
JP2018525019A (ja) 2018-09-06
AU2022203146A1 (en) 2022-06-02
EP3341477A1 (en) 2018-07-04
WO2017040348A1 (en) 2017-03-09
CN114875012B (zh) 2025-02-18
JP2021003110A (ja) 2021-01-14
AU2016316845B2 (en) 2022-03-10
EP3341477A4 (en) 2019-07-10
KR20240090567A (ko) 2024-06-21
JP2020010695A (ja) 2020-01-23
JP2021040644A (ja) 2021-03-18
JP6942848B2 (ja) 2021-09-29
KR20180042394A (ko) 2018-04-25
CN108350449B (zh) 2022-05-31
AU2016316845A1 (en) 2018-03-22
CA2996888A1 (en) 2017-03-09
KR102668608B1 (ko) 2024-05-24
JP2022023028A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
JP6799586B2 (ja) 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
US11060078B2 (en) Engineered CRISPR-Cas9 nucleases
US10633642B2 (en) Engineered CRISPR-Cas9 nucleases
JP7585373B2 (ja) 変更ＰＡＭ特異性を有する遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191206

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201120

R150 Certificate of patent or registration of utility model

Ref document number: 6799586

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250